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During one-year follow-up, 123 (15.2%) patients in the COR group and 40 (14.2%) in
the MVR group experienced at least one MACE (p=0.502). There were no differences
between the two groups in terms of rate of death, myocardial infarction, or
revascularization (2.1 vs. 2.0%, 0.7 vs. 0.8%, and 11.7 vs. 10.1%, respectively;
p=0.908, 0.908, and 0.540, respectively). The MACE rate was higher in the
incompletely revascularized patients than in the completely revascularized patients
(16.2 vs. 9.7%, p=0.017), and the difference was attributable to a higher rate of
nontarget vessel revascularization (8.6 vs. 1.8%, p=002).
Conclusion: Although multivessel angioplasty during primary PCI for STEMI did not
reduce the MACE rate compared with culprit-vessel-only PCI, complete
revascularization was associated with a lower rate of revascularization after multivessel
PCI.
TCT-63
Treatment Of Multivessel Coronary Artery Disease In Primary PCI for
STEMI: Culprit Only Revascularisation is Associated with Higher MACE
Rates
Oliver Guttmann, Daniel A Jones, Krishnaraj Rathod, Roshan Weerackody, M.
Akthar, Eleanor Wicks, Ajay Jain, Charles Knight, Anthony Mathur, Andrew Wragg
Barts and the Royal London NHS Trust, London, United Kingdom
Background: Multi-vessel disease occurs in 40-65% of patients undergoing Primary
PCI for STEMI and is associated with adverse prognosis. There is limited data
comparing outcomes of complete with infarct-related artery (IRA)-only
revascularisation in primary PCI for STEMI. We therefore sought to clarify the
outcome for those patients dependent on management strategy.
Methods: Prospective data of 2131 STEMI patients was analysed, who underwent
primary PCI between January 2004 and May 2010. Information was entered at the time
of procedure and outcome assessed by all-cause mortality information. Patients were
split into three different treatment groups: culprit vessel angioplasty-only (COR group);
staged revascularisation (SR group) and simultaneous treatment of non-IRA (CR
group). The primary end point used was MACE, defined as death, MI, stroke and TVR.
Results: There were 963 (45%) consecutive patients with STEMI and multivessel
CAD. There were similar baseline characteristics between the 3 groups, aside from
cardiogenic shock, which was significantly higher in the CR group. At 30 days of
follow up, 23/263 (9%) patients in the CR group experienced at least one major adverse
cardiac event (MACE), 1 (1%) in the SR group and 35 (5%) in the CR group (p=0.01).
This trend continued up to 1 year of follow up with the lowest rates of events in the
SR group. However after 3 years MACE rates are significantly increased in the COR
group (24%) but were similar in the CR (18%) and SR (17%) groups. MACE rates
were driven mainly by death in the CR with high rates of TVR in the COR and SR
groups.
Conclusion: Culprit vessel-only angioplasty was associated with the highest rate of
long-term MACE compared with multivessel treatment. Patients scheduled for staged
revascularisation experienced a similar rate of MACE to patients undergoing complete
simultaneous treatment of non-IRA.
TCT-64
Prasugrel Versus Double Clopidogrel to Overcome High Platelet Reactivity
Early Following a 600mg Clopidogrel Loading Dose In Patients Undergoing
Primary Percutaneous Coronary Intervention
Dimitrios Alexopoulos, Ioanna Xanthopoulou, Konstantinos Theodoropoulos,
George Kassimis, Theodora Plakomyti, Anastasia Galati, Grigorios Tsigkas, Ioannis
Chiladakis, Periklis Davlouros, George Hahalis
Cardiology Department, Patras University Hospital, Patras, Greece
Background: Platelet reactivity (PR) assessment in the very early phase (2 hours post
600mg clopidogrel loading dose-LD) of ST-elevation myocardial infarction (STEMI)
has not been previously reported nor any possible ways to overcome high on-treatment
PR (HTPR).
Methods: In STEMI patients undergoing primary PCI, PR was assessed with the
VerifyNow (Accumetrics Inc., San Diego, CA, USA) assay 2 hours after a 600mg
clopidogrel LD. Patients with HTPR (≥ 235 PR Units), were randomized to either
immediate reloading with 60mg prasugrel/10mg maintenance dose (MD) (group-A)
or clopidogrel 150mg MD starting from the next day (group-B). PR was re-assessed
at 2, 24 hours and at 5 days following randomization. Genotyping was performed for
CYP2C19*2 carriage.
Results: Out of 59 STEMI patients, 38(64.4%) demonstrated HTPR 2 hours post LD
and were all randomized (19 group-A and 19 group-B). PR 2 hours, 24 hours and 5
days post randomization was lower in group-A compared to group-B (Figure 1). HTPR
rate was lower for group-A compared to group-B at 24 hours post randomization in all
patients, in non-carriers and in carriers of 1 CYP2C19*2 loss-of-function allele (5.3%
vs 63.2%, p<0.001, 0% vs 57.1%, p=0.006 and 14.3% vs 100%, p=0.03 respectively).
Conclusion: In STEMI patients, HTPR 2 hours following 600 mg of clopidogrel LD
is very common. An additional reloading with 60 mg of prasugrel followed by a 10
mg MD, achieves greater platelet inhibition compared to clopidogrel 150 mg MD as
early as in 2 hours, a difference that is maintained up to 5 days.
TCT-65
Does Cytoprotector Mexicor Used Intracoronary during Rescue PCI Limit
Reperfusion Myocardial Injury in STEMI Patients?
Anton Koledinsky, Dmitry Gromov, Oleg Sukhorukov, Djamil Asadov, Natalia
Kuchkina, Pavel Vasiliev, David Iosseliani
Moscow City Center of Interventional Cardioangiology, Moscow, Russian
Federation
Background: To study the safety and efficacy of cytoprotector Mexicor (methyl-ethyl-
pyridinol succinate; EcoPharmInvest, Russia) used intracoronary in IRA followed by
angioplasty (stenting) within the first hours after the onset of STEMI.
Methods: The study comprised 191 STEMI patients (mean age 56±7) after successful
primary PCI of totally occluded (TIMI 0) IRA. Before PCI all patients were
randomized into two groups. Patients from Gr.1 (n=96) received 0,2 g of Mexicor in
100 ml of saline solution through microcatheter immediately after recanalization of
IRA before angioplasty. Gr.2 (n=95) comprised patients after successful PCI but
without intracoronary Mexicor use. Main baseline clinical, history and coronary
angiographic data were similar in all cases. Blood sampling for Troponine I was
performed prior to, and in 12 and 24 hours after the procedure. At day 10 as well as in
6 months all patients underwent repeat coronary angiography and left ventriculography.
Results: No complications related to intracoronary use of Mexicor were seen. Survival
during early follow-up was 98,06% in Gr.1 and 98,05% in Gr. 2. Total value of
Troponine I by 24th hour was 292,6±41,5 and 603,7±34,4 ng/ml, respectively (p<0,05).
At day 10 LV EF was 49,7±8,2 and 49,3±9,1, respectively In the mid-term (6,8±0,7
months) survival was 96,8% in Gr.1 and 92,7% in Gr. 2, LV EF was 53,1±9,4% and
48,7±8,3% (p<0,05).
Conclusion: The study suggests that the use of cytoprotector Mexicor intracoronary
in IRA immediately before angioplasty, in our opinion, is safe and limits reperfusion
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injury of the myocardium, which is evidenced by significantly lower Troponine I
indices in Gr.1 patients as well as better indices of left ventricular ejection fraction in
the same group.
TCT-66
Post-Procedural ST-segment Deviation is an Independent Predictor of Long-
Term Mortality in Patients Undergoing Primary Percutaneous Coronary
Intervention for ST-segment Elevation Myocardial Infarction
Wichert J Kuijt1, Niels J Verouden1, Peter Damman1, Joost D Haeck1, Karel T Koch1,
Jan G Tijssen1, Mitchell W Krucoff2, Robbert J De Winter1
1Cardiology, Academic Medical Center - University of Amsterdam, Amsterdam,
Netherlands; 2Duke University Medical Center, Durham, NC
Background: Post-procedural residual ST-segment deviation (STD) has been shown
to be a robust and easily assessed prognostic marker for patients undergoing primary
percutaneous coronary intervention (PCI) for ST-segment elevation myocardial
infarction (STEMI). Recent studies have identified pre-procedural serum biochemical
markers predictive of long-term mortality. We investigated the independent additional
value of post-procedural residual STD after accounting for these novel biomarkers.
Methods: We analyzed 530 STEMI patients who underwent primary PCI at our
institution in 2005 – 2006. Samples for C-reactive protein, Troponin T, creatinin, NT-
pro BNP and glucose were acquired from the arterial sheath prior to diagnostic
angiography. ECGs were recorded in the catheterization laboratory at last contrast
injection of the PCI procedure. STD was defined as the sum of cumulative ST-segment
elevation and depression in all 12 leads and trichotomized as 0-2 mm, 2-4 mm and >4
mm of residual deviation. Mortality was assessed at 3-year follow-up.
Results: All biochemical markers and post-procedural STD were predictive of 3-year
mortality in univariable analysis. In multivariable cox-regression analysis, post-
procedural STD (HR 2.12, 95% CI 1.47 - 3.06; P<0.001), creatinin (HR 1.01, 95% CI
1.00 – 1.02; P=0.012), glucose (HR 1.07, 95% CI 1.02 – 1.12; P=0.006) and NT-pro
BNP (HR 1.00, 95% CI 1.00 – 1.00; P<0.001) were predictive of long-term outcome.
Finally, after adjusting for clinical risk factors, post-procedural STD (HR 1.81, 95%
CI 1.17 – 2.82; P=0.008) and NT-pro BNP (HR 1.00, 95% CI 1.00 – 1.00; P=0.012)
remained independent predictors of death at 3-year follow-up.
Conclusion: After adjustment for clinical risk factors and other admission biochemical
markers, post-procedural STD and NT-pro BNP were independent predictors of 3-year
mortality. These results reaffirm the importance of rapid and complete normalization
of the ECG as a marker of successful myocardial reperfusion.
TCT-67
Incremental Value of Thrombus Age to Multiple Biomarkers for the Prediction
of 1-year Mortality after ST-segment Elevation Myocardial Infarction
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Allard C van der Wal3, Jan P van Straalen2, Karel T Koch1, Jose P Henriques1, Jan
Baan1, Marije M Vis1, Jan J Piek1, Johan C Fischer2, Jan G Tijssen1, Robbert J de
Winter1
1Department of Cardiology, Academic Medical Center - University of Amsterdam,
Amsterdam, Netherlands; 2Department of Clinical Chemistry, Academic Medical
Center - University of Amsterdam, Amsterdam, Netherlands; 3Department of
Pathology, Academic Medical Center - University of Amsterdam, Amsterdam,
Netherlands
Background: We have previously shown that older thrombus is associated with a
significant 2-fold higher long-term mortality in STEMI patients after pPCI.
Methods: STEMI patients who were treated in our center with thrombus aspiration
were included if aspirated thrombus material could histopathologically be classified
according to thrombus age and laboratory measurements of at least one biomarker
(tropT, glucose, NT-proBNP, estimated GFR, and CRP) was available. The additional
prognostic value of thrombus age beyond multiple biomarkers and established clinical
risk factors was evaluated in multivariate Cox models.
Results: Serum biomarker levels were similar between patients with fresh and older
thrombus. 60 patients(7%)died within 1 year. Thrombus age remained strongly
associated with 1-year mortality after multivariable adjustment for multiple biomarkers
and established clinical risk factors (HR 2.81; 95%CI 1.45 to 5.43; p=0.002). Addition
of thrombus age to either a model including established clinical risk factors and
biomarkers or a model including solely biomarkers resulted in significant increases in
the discriminative value, as evidenced by net reclassification improvement (0.42;
p<0.01) and integrated discriminative improvement (0.022; p=0.04).
Conclusion: Thrombus age provides independent complementary information to a
multimarker model including established clinical risk factors and multiple biomarkers
for predicting 1-year mortality in STEMI patients treated with pPCI and thrombus
aspiration.
TCT-68
Increased mortality with post-infarct ventricular septal ruptures at a tertiary
care center
Lawrence D Lazar2, 1, Samir R Kapadia1, E. Murat Tuzcu1, Venu Menon1
1Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH;
2Division of Interventional Cardiology, David Geffen School of Medicine at UCLA,
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Background: Post-infarct ventricular septal rupture (PVSR) is a highly morbid
complication of myocardial infarction (MI). Surgical case series fail to capture the
outcomes across the universe of this entity. We therefore sought to describe our
outcomes of all acute PVSRs, with cases identified independent of intervention or
survival.
Methods: The Cleveland Clinic echocardiography database was searched for all
patients with ventricular septal defect or rupture, 1/1/2000 to 4/15/2011. Patients
referred greater than 30 days from index event were excluded.
Results: We identified 69 acute PVSRs from 2000 to 2011, with median time from
onset of MI symptoms to VSR of 5 days. 45 cases (65%) were managed surgically, 16
(23%) medically, 7 (10%) percutaneously, and 1 (1%) transplanted. Percutaneous cases
had been turned down for surgery and had a mean time from VSR to intervention of
2.3 days. One-year mortalities were determined: overall (68%), surgical (56%), medical
(94%), percutaneous (100%), and transplant (0%). Overall mortality was associated
with higher troponin (p=0.016) and RV dysfunction (p=0.017). 33% of cases were
LAD infarcts, which had higher likelihood of non-surgical care (p=0.0005), and had a
78% mortality rate, compared with 62% for RCA infarcts. Notable variables not
associated with management or outcome included admission blood pressure, heart rate,
creatinine, ejection fraction, shunt fraction, or response to balloon pump. There was a
trend of increased mortality in the second-half of the observation period (59% vs 80%,
p=0.06), along with trends of increased history of smoking, prior bypass surgery, and
elevated creatinine.
Conclusion: Current outcomes with acute PVSR remain dismal. Mortality appears to
be rising over the past decade, which we attribute to a more infirm referral population.
In this tertiary care center, outcomes of inoperable patients with acute PVSRs treated
percutaneously or medically were very poor. Aggressive percutaneous hemodynamic
support and earlier treatment may improve outcomes of these patients.
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